Exosome Production Method for Cancer Therapeutic Delivery

USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.

Nanoparticulate drug delivery for therapeutic applications

The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.

Cisplatin-Eugenol Analogue for Cancer Treatment

The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.

Probiotics to prevent cognitive dysfunction

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

Mesembrine Crystalline Salt Patent Grant

USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.

Thiosemicarbazates and Uses Thereof

The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.

2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent

USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.

STAT3 inhibitor prodrug patent compositions

USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.

Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors

USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.

MDM2 Inhibitor Patent Granted to Bahcesehir University

The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.